8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
Jun 9, 2026·SEC
Material company update
Jun 5, 2026·SEC
Aditxt, Inc.(ADTX)Earnings, Financials & Key Ratios
ADTX•NASDAQ
Price updated Jun 19, 2026
AboutAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Show more
- Revenue$3K-97.6%
- EBITDA-$19M+29.2%
- Net Income-$42M-21.1%
- EPS (Diluted)-1153.83+62.3%
- Gross Margin8.39%+102.3%
- EBITDA Margin-604010.02%-2870.2%
- Operating Margin-612542.22%-2845.4%
- Net Margin-1305608.79%-4978.4%
- ROE-681.6%-140.7%
ADTX Key Insights
Aditxt, Inc. (ADTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Profits declining 35.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 0 (bottom 0%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADTX Price & Volume
Aditxt, Inc. (ADTX) stock price & volume — 10-year historical chart
Loading chart...
ADTX Growth Metrics
Aditxt, Inc. (ADTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-84.93%
TTM-74.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-104.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1269.9%
Return on Capital
10 Years-248.64%
5 Years-259.02%
3 Years-235.23%
Last Year-300.31%
ADTX Peer Comparison
Aditxt, Inc. (ADTX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMMP | 55.08M | 0.37 | -1.27 | 31.28% | -11.72% | -72.51% | 0.01 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AIMD | 8.69M | 1.92 | -0.55 | 498.95% | -769.96% | -160.55% | 1.45 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare ADTX vs Peers
Aditxt, Inc. (ADTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADTX Income Statement
Aditxt, Inc. (ADTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 105.03K | 933.72K | 645.18K | 133.99K | 3.19K | 14.34K |
Revenue Growth % | - | - | - | - | - | 788.96% | -30.9% | -79.23% | -97.62% | -74.09% |
Cost of Goods Sold | 0 | 0 | 0 | 17.77K | 77.98K | 766.78K | 756.84K | 627.47K | 2.93K | 11.48K |
COGS % of Revenue | - | - | - | - | 74.24% | 82.12% | 117.31% | 468.32% | 91.61% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -17.77K▲ 0% | 27.05K▲ 252.2% | 166.94K▲ 517.0% | -111.66K▼ 166.9% | -493K▼ 341.5% | 268▲ 100.1% | 2.85K▲ 0% |
Gross Margin % | - | - | - | - | 25.76% | 17.88% | -17.31% | -367.95% | 8.39% | 19.89% |
Gross Profit Growth % | - | - | - | - | 252.23% | 517.02% | -166.89% | -341.52% | 100.05% | - |
Operating Expenses | 212.99K | 5.61M | 5.87M | 8.85M | 41.96M | 25.65M | 25.95M | 27.37M | 19.57M | 18.33M |
OpEx % of Revenue | - | - | - | - | 39950.87% | 2746.77% | 4022.28% | 20427.66% | 612550.61% | - |
Selling, General & Admin | 212.99K | 5.08M | 5.7M | 7.92M | 22.42M | 17.84M | 18.88M | 16.48M | 16.38M | 15.3M |
SG&A % of Revenue | - | - | - | - | 21344.52% | 1910.11% | 2925.78% | 12302.87% | 512577.75% | - |
Research & Development | 0 | 525K | 175.44K | 937.97K | 5.04M | 7.27M | 7.07M | 10.89M | 3.19M | 3.03M |
R&D % of Revenue | - | - | - | - | 4801.3% | 778.4% | 1096.5% | 8124.79% | 99972.86% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 14.5M | 544.03K | 0 | 0 | 0 | 0 |
Operating Income | -213K▲ 0% | -5.61M▼ 2533.3% | -5.87M▼ 4.7% | -8.87M▼ 51.1% | -41.94M▼ 372.7% | -25.48M▲ 39.2% | -26.06M▼ 2.3% | -27.86M▼ 6.9% | -19.57M▲ 29.8% | -18.32M▲ 0% |
Operating Margin % | - | - | - | - | -39925.17% | -2728.88% | -4039.58% | -20796.36% | -612542.22% | -127821.37% |
Operating Income Growth % | - | -2533.33% | -4.67% | -51.12% | -372.66% | 39.24% | -2.29% | -6.91% | 29.76% | - |
EBITDA | 638.94K | 0 | 0 | -8.85M | -41.46M | -24.94M | -25.52M | -27.25M | -19.3M | -18.07M |
EBITDA Margin % | - | - | - | - | -39471.76% | -2671.48% | -3955.49% | -20335.67% | -604010.02% | -126063.3% |
EBITDA Growth % | - | -100% | - | - | -368.23% | 39.83% | -2.31% | -6.77% | 29.17% | 15.52% |
D&A (Non-Cash Add-back) | 851.94K | 5.61M | 5.87M | 17.77K | 476.24K | 535.98K | 542.58K | 617.25K | 272.6K | 252.04K |
EBIT | -213K | -5.61M | -5.83M | -8.84M | -44.43M | -25.36M | -26M | -27.66M | -40.4M | -50.94M |
Net Interest Income | 0 | 0 | 0 | -309.52K | -1.94M | -2.23M | -6.38M | -7.36M | -2.19M | -1.82M |
Interest Income | 0 | 0 | 1.93K | 563 | 3.1K | 57.35K | 10.17K | 1.45K | 200.18K | 200.17K |
Interest Expense | 0 | 79.77K | 1.93K | 310.08K | 1.94M | 2.29M | 6.39M | 7.36M | 2.39M | 2.08M |
Other Income/Expense | 0 | -79.77K | 43.07K | -277.02K | -4.44M | -2.17M | -6.33M | -7.16M | -23.22M | -34.7M |
Pretax Income | -852K▲ 0% | -5.69M▼ 567.7% | -5.83M▼ 2.4% | -9.15M▼ 57.0% | -46.37M▼ 406.8% | -27.65M▲ 40.4% | -32.39M▼ 17.1% | -35.02M▼ 8.1% | -42.79M▼ 22.2% | -53.02M▲ 0% |
Pretax Margin % | - | - | - | - | -44148.56% | -2961.29% | -5020.4% | -26137.25% | -1339187.57% | -369864.52% |
Income Tax | -852K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 100% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -213K▲ 0% | -5.69M▼ 2570.9% | -5.83M▼ 2.5% | -9.15M▼ 56.9% | -46.37M▼ 406.8% | -27.65M▲ 40.4% | -32.38M▼ 17.1% | -34.45M▼ 6.4% | -41.71M▼ 21.1% | -51.95M▲ 0% |
Net Margin % | - | - | - | - | -44148.56% | -2961.29% | -5018.92% | -25708.85% | -1305608.79% | -362385.72% |
Net Income Growth % | - | -2570.89% | -2.47% | -56.94% | -406.83% | 40.37% | -17.11% | -6.38% | -21.1% | -104.32% |
Net Income (Continuing) | -213K | -5.69M | -5.83M | -9.15M | -46.37M | -27.65M | -32.39M | -35.02M | -42.79M | -53.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -9.61K | -583.18K | -1.66M | -1.9M |
EPS (Diluted) | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | -3062.42▲ 0% | -1153.83▲ 62.3% | -2575.18▲ 0% |
EPS Growth % | - | - | - | - | - | - | - | - | 62.32% | -1269.9% |
EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3062.42 | -1153.83 | - |
Diluted Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.18K | 37.35K | 20.17K |
Basic Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.25K | 37.35K | 20.17K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ADTX Balance Sheet
Aditxt, Inc. (ADTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25K | 115.71K | 4.09K | 11.03M | 9.42M | 4.74M | 6.91M | 2M | 3.82M | 850.01K |
Cash & Short-Term Investments | 25K | 115.71K | 4.09K | 10.5M | 7.87M | 2.77M | 97.1K | 833.03M | 3.2B | 268.85K |
Cash Only | 25K | 115.71K | 4.09K | 10.5M | 7.87M | 2.77M | 97.1K | 833.03K | 833.03K | 268.85K |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 832.2M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 589.84K | 527.96K | 5.85M | 1.15M | 0 | 11.97K |
Days Sales Outstanding | - | - | - | - | 2.05K | 206.39 | 3.31K | 3.14K | - | 578.58 |
Inventory | 0 | 0 | 0 | 0 | 494.7K | 950.09K | 745.5K | 11.24K | 5.77M | 128.37K |
Days Inventory Outstanding | - | - | - | - | 2.32K | 452.26 | 359.53 | 6.54 | 720.02K | 47.01K |
Other Current Assets | 0 | 0 | 0 | 384.69K | 0 | 0 | 0 | -885.71M | -3.2B | 0 |
Total Non-Current Assets | 0 | 0 | 119.44K | 2.06M | 7.25M | 5.99M | 37.67M | 30.14M | 12.7M | 13.06M |
Property, Plant & Equipment | 0 | 0 | 0 | 1.67M | 6.36M | 5.48M | 4.1M | 2.77M | 2.08B | 1.78M |
Fixed Asset Turnover | - | - | - | - | 0.02x | 0.17x | 0.16x | 0.05x | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 537.38K |
Intangible Assets | 0 | 0 | 0 | 321K | 214K | 107K | 9.44K | 6.11K | 2.78M | 1.94K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 22.28M | 27.28M | 10.55M | 57.77M |
Other Non-Current Assets | 0 | 0 | 119.44K | 72.3K | 668.79K | 405.37K | 11.28M | -310.19K | -2.09B | 61.59K |
Total Assets | 25K▲ 0% | 115.71K▲ 362.8% | 123.53K▲ 6.8% | 13.1M▲ 10501.7% | 16.66M▲ 27.2% | 10.74M▼ 35.6% | 44.58M▲ 315.3% | 32.14M▼ 27.9% | 16.52M▼ 48.6% | 13.91M▲ 0% |
Asset Turnover | - | - | - | - | 0.01x | 0.09x | 0.01x | 0.00x | 0.00x | 0.00x |
Asset Growth % | - | 362.84% | 6.76% | 10501.71% | 27.24% | -35.58% | 315.25% | -27.89% | -48.62% | -149.32% |
Total Current Liabilities | 59.9K | 1.65M | 2.98M | 1.23M | 3.61M | 3.64M | 25.89M | 23.41M | 12.22M | 13.34M |
Accounts Payable | 8.57K | 1.06M | 1.85M | 241.61K | 1.58M | 1.96M | 8.55M | 10.19M | 7.34M | 7.73M |
Days Payables Outstanding | - | - | - | 4.96K | 7.37K | 932.28 | 4.13K | 5.93K | 915.37K | 279K |
Short-Term Debt | 0 | 163.6K | 165.6K | 587.59K | 700.43K | 409.98K | 16.18M | 5.8M | 2.66B | 3.31M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | -1.58M | -1.96M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 51.33K | 0 | 0 | 6.54K | 1.76M | 2.15M | 158.61K | 4.48M | -2.66B | 1.67M |
Current Ratio | 0.42x | 0.07x | 0.00x | 8.99x | 2.61x | 1.30x | 0.27x | 0.09x | 0.31x | 0.06x |
Quick Ratio | 0.42x | 0.07x | 0.00x | 8.99x | 2.47x | 1.04x | 0.24x | 0.08x | -0.16x | 0.05x |
Cash Conversion Cycle | - | - | - | - | -3.01K | -273.63 | -455.04 | -2.78K | - | -231.41K |
Total Non-Current Liabilities | 25K | 1.22M | 0 | 858.06K | 2.88M | 1.89M | 2.64M | 450.87K | 342.91M | 35.74M |
Long-Term Debt | 0 | 0 | 0 | 0 | 110.04K | 0 | 0 | 0 | 342.9M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 858.06K | 2.77M | 1.89M | 1.04M | 436.35K | 342.9K | 745.15K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 25K | 0 | 0 | 0 | 0 | 0 | 1.6M | 14.52K | 0 | 35.45M |
Total Liabilities | 84.9K | 1.65M | 2.98M | 2.09M | 6.48M | 5.53M | 28.53M | 23.86M | 12.56M | 49.08M |
Total Debt | 0 | 163.6K | 165.6K | 1.84M | 4.72M | 3.38M | 18.22M | 6.92M | 6.92M | 4.23M |
Net Debt | -25K | 47.89K | 161.51K | -8.66M | -3.15M | 613.22K | 18.12M | 6.09M | 6.09M | 3.96M |
Debt / Equity | - | - | - | 0.17x | 0.46x | 0.65x | 1.14x | 0.84x | 1.75x | -0.12x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.23x |
Net Debt / EBITDA | -0.04x | - | - | - | - | - | - | - | - | -0.22x |
Interest Coverage | - | -70.32x | -3018.55x | -28.51x | -22.92x | -11.10x | -4.07x | -3.76x | -16.92x | -24.47x |
Total Equity | -59.9K▲ 0% | -1.54M▼ 2465.5% | -2.85M▼ 85.6% | 11.01M▲ 486.1% | 10.18M▼ 7.5% | 5.21M▼ 48.9% | 16.05M▲ 208.2% | 8.29M▼ 48.4% | 3.95M▼ 52.3% | -35.17M▲ 0% |
Equity Growth % | - | -2465.5% | -85.6% | 486.07% | -7.54% | -48.86% | 208.22% | -48.36% | -52.29% | -585.45% |
Book Value per Share | - | - | - | 0.85 | 0.23 | 1.21 | 12.17 | 628.85 | 105.84 | -1743.55 |
Total Shareholders' Equity | -59.9K | -1.54M | -2.85M | 11.01M | 10.18M | 5.21M | 16.06M | 8.87M | 5.61M | -33.28M |
Common Stock | 7.1K | 7.53K | 3.92K | 13.08K | 44.53K | 4.31K | 1.32K | 130 | 412 | 39 |
Retained Earnings | -212.99K | -5.9M | -11.73M | -20.88M | -67.35M | -95.04M | -127.74M | -168.09M | -209.81M | -225.76M |
Treasury Stock | 0 | 0 | -189.63K | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K | -201.6K |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.25M | 1.36M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -9.61K | -583.18K | -1.66M | -1.9M |
ADTX Cash Flow Statement
Aditxt, Inc. (ADTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 0 | -386.26K | -464.35K | -7.22M | -22.28M | -22.39M | -18.58M | -16.76M | -25.69B | -18.55M |
Operating CF Margin % | - | - | - | - | -21210.41% | -2398.16% | -2879.34% | -12510.45% | -99999900% | - |
Operating CF Growth % | - | - | -20.22% | -1455.07% | -208.52% | -0.51% | 17.04% | 9.77% | -153152.44% | 7.19% |
Net Income | -851.94K | -5.69M | -5.83M | -9.15M | -46.37M | -27.65M | -32.38M | -34.45M | -42.79B | -51.95M |
Depreciation & Amortization | 0 | 0 | 0 | 17.77K | 476.24K | 535.98K | 542.58K | 617.25K | 272.6M | 272.58M |
Stock-Based Compensation | 612.34K | 3.52M | 4.23M | 3.19M | 4.64M | 3.13M | 1.4M | 6.75M | 473.31M | 473.3M |
Deferred Taxes | 0 | 0 | 0 | 0 | 17M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 34.26K | 350.51K | 0 | 300K | 1.85M | 2.08M | 2.76M | 3.23M | 16.36B | 42.03B |
Working Capital Changes | 205.34K | 1.43M | 1.13M | -1.58M | 129.97K | -493.44K | 9.1M | 7.09M | -6.17M | -415.52K |
Change in Receivables | 0 | 0 | 0 | 0 | -89.84K | -36.77K | 119.64K | 364.89K | 43.44K | 30.14K |
Change in Inventory | 0 | 0 | 0 | 0 | -494.7K | -455.4K | 204.59K | 734.26K | 5.47K | 12.57K |
Change in Payables | 0 | 1.05M | 601.61K | -1.48M | 1.33M | 412.96K | 6.65M | 5.1M | -5.63M | -316.06K |
Cash from Investing | 0 | 0 | 0 | -170.63K | -16.31M | -241.92K | -14.41K | -5M | -2.44B | -24.12K |
Capital Expenditures | 0 | 0 | 0 | -170.63K | -1.02M | -367.08K | -14.41K | 0 | -13.74M | -13.75M |
CapEx % of Revenue | - | - | - | - | 967.07% | 39.31% | 2.23% | 0% | 430140.85% | 95935.96% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -15.29M | 125.16K | 0 | 0 | -2.42B | 11.3M |
Cash from Financing | 100K | 476.97K | 352.73K | 17.89M | 35.95M | 17.53M | 16.55M | 22.5M | 30.49B | 20.8M |
Debt Issued (Net) | 0 | 119.5K | 2K | -354.07K | 3.56M | -411.89K | 4.86M | -1.4M | -5.54M | 3.95M |
Equity Issued (Net) | 0 | 631.22K | 470.18K | 18.29M | 29.87M | 17.23M | 11.05M | 18.31M | 34.92M | 28.48M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.35M |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -20K | -1K | -2.85M | -9.21M | -1.87M |
Other Financing | 100K | -273.75K | -119.44K | -45K | 2.53M | 709.08K | 627.86K | 5.58M | 30.46B | -12.68M |
Net Change in Cash | 100K▲ 0% | 90.71K▼ 9.3% | -111.62K▼ 223.1% | 10.5M▲ 9504.1% | -2.63M▼ 125.0% | -5.1M▼ 94.1% | -2.67M▲ 47.7% | 735.93K▲ 127.5% | 2.37B▲ 321339.7% | -207.56K▲ 0% |
Free Cash Flow | 0▲ 0% | -386.26K▲ 0% | -464.35K▼ 20.2% | -7.39M▼ 1491.8% | -23.29M▼ 215.1% | -22.76M▲ 2.3% | -18.59M▲ 18.3% | -16.76M▲ 9.8% | -25.7B▼ 153234.4% | -18.58M▲ 0% |
FCF Margin % | - | - | - | - | -22177.48% | -2437.48% | -2881.57% | -12510.45% | -99999900% | -129588.46% |
FCF Growth % | - | - | -20.22% | -1491.82% | -215.14% | 2.3% | 18.31% | 9.84% | -153234.43% | 17.49% |
FCF per Share | - | - | - | -0.57 | -0.52 | -5.29 | -14.10 | -1272.07 | -688049.85 | -920.88 |
FCF Conversion (FCF/Net Income) | - | 0.07x | 0.08x | 0.79x | 0.48x | 0.81x | 0.57x | 0.49x | 615.82x | 0.36x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADTX Key Ratios
Aditxt, Inc. (ADTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -224.26% | -437.62% | -359.39% | -304.72% | -283.12% | -681.6% | 739.92% |
Return on Invested Capital (ROIC) | - | - | - | -670.76% | -297.44% | -97.77% | -86.1% | -120.24% | 667.54% |
Gross Margin | - | - | - | 25.76% | 17.88% | -17.31% | -367.95% | 8.39% | 19.89% |
Net Margin | - | - | - | -44148.56% | -2961.29% | -5018.92% | -25708.85% | -1305608.79% | -362385.72% |
Debt / Equity | - | - | 0.17x | 0.46x | 0.65x | 1.14x | 0.84x | 1.75x | -0.12x |
Interest Coverage | -70.32x | -3018.55x | -28.51x | -22.92x | -11.10x | -4.07x | -3.76x | -16.92x | -24.47x |
FCF Conversion | 0.07x | 0.08x | 0.79x | 0.48x | 0.81x | 0.57x | 0.49x | 615.82x | 0.36x |
Revenue Growth | - | - | - | - | 788.96% | -30.9% | -79.23% | -97.62% | -74.09% |
Related:ADTX Dividend History·ADTX Revenue History·ADTX Price History·ADTX P/E History·ADTX Financial Ratios·ADTX Institutional Holders
ADTX SEC Filings & Documents
Aditxt, Inc. (ADTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ADTX Frequently Asked Questions
Aditxt, Inc. (ADTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aditxt, Inc. (ADTX) reported $0.0M in revenue for fiscal year 2025.
Aditxt, Inc. (ADTX) saw revenue decline by 97.6% over the past year.
Aditxt, Inc. (ADTX) reported a net loss of $52.0M for fiscal year 2025.
Dividend & Returns
Aditxt, Inc. (ADTX) has a return on equity (ROE) of -681.6%. Negative ROE indicates the company is unprofitable.
Aditxt, Inc. (ADTX) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.